Sean F. Scanlan, Chief Innovation Officer at TREACE MEDICAL CONCEPTS, INC. (TMCI), sold 50,000 shares at $7.97 ($399K) on 2025-03-17, disclosed to the SEC on 2025-03-19.
Scheduled sale ($398k) by Chief Innovation Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TMCI | SELL | 2023-02-17 | $542K | — | Filing → |
| TMCI | SELL | 2023-01-13 | $639K | — | Filing → |
| TMCI | SELL | 2022-11-16 | $607K | — | Filing → |